Related Experiment Video

Updated: May 12, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma

Bethany Mikles1, Jennifer Levine, Tatyana Gindin

  • 1*Division of Pediatric Hematology/Oncology, Naval Medical Center Portsmouth, Portsmouth, VA Departments of †Pediatric Oncology/Blood and Marrow Transplant ‡Pathology, Columbia University Medical Center, NY Presbyterian Hospital, New York, NY.

Journal of Pediatric Hematology/Oncology
|April 17, 2013
PubMed

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...